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Nerve biopsy represents the conclusive step in the diagnostic work-up of peripheral
neuropathies, and its diagnostic yield is still debated. The aim of this study is to
consider the impact of nerve biopsy on reaching a useful diagnosis in different peripheral
neuropathies and its changing over time. We retrospectively analyzed 1,179 sural
nerve biopsies performed in the period 1981–2017 at Neurological Clinic of Policlinico
San Martino (Genoa). We relied on medical records and collected both clinical and
pathological data in a database. Biopsy provided univocal diagnoses in 53% of cases
(with an increase over time), multiple diagnostic options in 14%, while diagnosis was
undetermined in 33% (undetermined reports decreased during the years). In 57% of
patients, the pre-biopsy suspicion was confirmed, while in 43% sural biopsy modified
the clinical diagnosis. The highest yield was in axonal neuropathies (29% undetermined
reports vs. 40% in demyelinating and 48% inmixed neuropathies). In 68% of patients with
vasculitic neuropathy, this etiology was already suspected, whereas in 32% nerve biopsy
modified the clinical diagnosis. During the years, the number of annually performed
biopsies decreased significantly (p = 0.007), with an increase in the mean age of
patients (p < 0.0001). The percentage of hereditary neuropathies had a significant
decrease (p = 0.016), while the rate of vasculitic and chronic inflammatory neuropathies
increased (p < 0.0001). This is the largest Italian study addressing the yield of sural
nerve biopsy. During the years, we observed a progressive refinement of the indication
of this procedure, which confirms its utility for interstitial neuropathies, particularly if
non-systemic vasculitic neuropathy is suspected.
Keywords: sural nerve biopsy, vasculitic neuropathy, amyloidotic neuropathy, neuropathy, axonal neuropathies,
demyelinating neuropathies
INTRODUCTION
Peripheral neuropathies represent one of the main neurological diseases, with a prevalence of 2.4%
in general population, reaching 8% in people older than 55 (1). The diseases that can lead to a
polyneuropathy are more than one hundred (2). Diagnosis is usually achieved by means of medical
history, physical examination, electrophysiology, laboratory tests, and possibly cerebrospinal fluid
examination, imaging, and genetic testing (1, 3–5). Sural nerve biopsy usually represents the
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conclusive step in the diagnostic work-up of several peripheral
neuropathies. It is an invasive procedure, so it is applied
only in cases unresolved after an extensive workout; when
successful it can modify the subsequent therapeutic choices (5–
7). The main consequence of biopsy is an area of cutaneous
anesthesia at the lateral margin of foot, in the territory
previously innervated by sural nerve. Major complications, such
as neuroma formation or wound infections occur in 1% of
patients, moreover in patients affected by vasculitis receiving
corticosteroid therapy, this may result in delayed healing (8–
12). It is known and demonstrated that only few peripheral
neuropathies require biopsy (7), but in some cases this procedure
may be indispensable for diagnosis (5). Currently, the main
indication of nerve biopsy is restricted to the investigation
of treatable causes of neuropathy. In effect, this procedure is
particularly useful to diagnose interstitial neuropathies, such
as vasculitis, granulomatosis, leprosy, amyloidosis or tumors,
but also to confirm a chronic inflammatory demyelinating
polyneuropathy with atypical presentation (6, 7).
Clinical utility (5, 13, 14), indications, timing, site (15–20),
and execution methods of nerve biopsy are still a topic of
discussion within clinical and scientific community (6, 7, 21–
24). While some authors emphasize the importance of biopsy in
cryptogenic neuropathies (12), others do not. According to most
authors, the main indication for nerve biopsy is the suspicion of
vasculitic neuropathy (7, 12). Identifying groups of patients that
should not undergo this procedure would lower the percentage
of uninformative biopsies (12). The extensive series of cases
at the Neurological Clinic of Policlinico San Martino (Genoa)
is a unique asset to answer these questions. In fact, over a
period of 37 years, more than a thousand biopsy samples were
examined. Moreover, since 2018, the Neuropathology Laboratory
has become a real Biobank, devoted to both maintenance
and sharing of biological material for diagnostic and research
purposes. The first question we wanted to answer with this study
is the diagnostic return of nerve biopsy in our neuropathology
laboratory. The second question was to evaluate how the behavior
of clinicians and neuropathologists dedicated to interpretation
of histological material has changed over the years. We also
decided to evaluate how indications of nerve biopsy have changed
during the years, in order to highlight the cases in which biopsy
can still have a diagnostic meaning. Finally, we analyzed the
correspondence between the histological and clinical suspicion
in order to evaluate the impact of nerve biopsy in modifying the
pre-biopsy diagnosis.
MATERIALS AND METHODS
We retrospectively analyzed 1,184 medical records of the sural
nerve biopsies performed in the period 1981–2017 at the
Neuropathology Laboratory of Neurological Clinic of Policlinico
San Martino (Genoa). Excluding 5 missing histological reports,
we analyzed 1,179 reports of sural nerve biopsy and collected
Abbreviations: CMT1A, Charcot Marie Tooth type 1A; CIDP, Chronic
Inflammatory Demyelinating Polineuropathy; PNS, Peripheral Nervous System;
MAG, Myelin Associated Glycoprotein.
both clinical and pathological data in a database Excel format
(data are summarized in Figure 1).
In the presence of a precise pre-biopsy clinical suspicion, we
calculated the percentage of patients in whom this suspicion
was confirmed by histological examination and in which instead
the biopsy modified the clinical diagnosis. Considering the cases
in which histology did not provide diagnostic indications, we
assessed what the clinical suspicion was and we focused on the
yield of biopsy in neuropathies of unknown origin.
Regarding patients with a histological picture of vasculitis,
we analyzed the available medical records to assess what was
the initial hypothesis and the percentage of different types of
vasculitis encountered.
Considering the patients with histologically diagnosed
hereditary neuropathy since 1991, year of identification of
17p11.2 chromosome duplication as responsible for Charcot
Marie Tooth type 1A (CMT1A) (25, 26), we assessed the
subsequent molecular confirmation of the diagnosis. We then
looked for these patients on a database containing the genetic
test reports.
We used linear regression and Spearman correlation
coefficient R to analyze the decrease of the number of annually
performed biopsies, the increase in the average age of patients
and the reduction of the percentage of minors. We also evaluated
the trend of the percentage of indeterminate reports and univocal
diagnoses over the years. Finally, we considered whether certain
categories of neuropathy, in particular hereditary, toxic-
deficient, chronic inflammatory and vasculitic forms, showed
either a decrease or an increase. Results were considered
statistically significant in the presence of p < 0.05.
RESULTS
The total number of analyzed biopsies is 1,179. The number of
annually performed biopsies has undergone a significant decrease
(r2 = 0.19, p= 0.007, Figure 2).
The mean age of patients is 46 years (range 5 months
to 87 years, Supplementary Material for a data resume). The
average age of patients who underwent sural nerve biopsy has
significantly increased over the years (r2 = 0.64, p < 0.0001,
Figure 3A). There were 87 minors (0–17 years old), including
57 males and 30 females. The percentage of minors significantly
decreased from 1981 to 2017 (r2 = 0.35, p= 0.0001, Figure 3B).
The univocal diagnoses were 52.7% (n = 621), the cases in
which biopsy provided multiple diagnostic options were 13.7%
(n= 162), and indeterminate reports were 33.6% (n= 396).
During the years, the percentage of unique diagnoses
increased (r2 = 0.12, p = 0.04, Figure 4A), while the percentage
of indeterminate histological findings significantly decreased
(r2 = 0.3, p= 0.0004, Figure 4B).
In axonal neuropathies, some diagnostic indication was
obtained in 71% of cases (n = 281), while the report was
indeterminate in the remaining 29% (n = 114). Regarding
demyelinating neuropathies, instead, histological examination
provided diagnostic indications in 60.5% (n = 245) and did
not contribute to the achievement of an etiological diagnosis in
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FIGURE 1 | Selection criteria.
FIGURE 2 | Number of sural nerve biopsies performed during each year from
1981 to 2017. There is a statistically significant decrease in the number of
annually performed histological investigations, with r2 = 0.19 and p = 0.007.
**p < 0.01.
39.5% of cases (n = 160). In mixed neuropathies, in which it
was therefore not possible to identify whether the pathological
process was initially axonal or demyelinating, the reports were
indeterminate in 48% of cases (n = 106), while it was possible to
formulate diagnostic hypotheses in the remaining 52% (n= 115).
Considering the 87 minors, nerve was normal in 18 cases,
histological report was indeterminate in 32, genetic neuropathy
was diagnosed in 30, and dysimmune neuropathy in 2 patients
(1 Guillain-Barré syndrome and 1 chronic relapsing idiopathic
polyneuritis). In the remaining 5 cases a double diagnostic
hypothesis was formulated, i.e., hereditary neuropathy or chronic
inflammatory demyelinating polineuropathy (CIDP).
The proportion of hereditary neuropathies significantly
decreased over time (r2 = 0.22, p = 0.016, Figure 5A). The
percentage of vasculitic and chronic inflammatory neuropathies
has instead undergone a statistically significant increase
(r2 = 0.38 and p < 0.0001 for chronic inflammatory
neuropathies; r2 = 0.57 and p < 0.0001 for vasculitis,
Figures 5B,C). On the other hand, toxic-deficient and metabolic
neuropathies underwent a percentage reduction (r2 = 0.22 and
p= 0.0038, Figure 5D).
Considering 332 patients for whom one or more clinical
suspects were available (excluding cases in which clinical
suspicion lacked), in 190 (57.2%) clinical suspicion was
confirmed by nerve biopsy, while in the remaining 142 cases
(42.8%) nerve biopsy modified the clinical diagnosis.
Among 396 patients for whom nerve biopsy did not provide
diagnostic indications, in 71.5% (n = 283) of cases a precise
etiological hypothesis was missing even before histological
examination. On the contrary, considering 708 patients with
an absent clinical suspicion, in 38.9% of cases (n = 275) the
histological report was indeterminate, while in 61.1% of cases
(n= 433) biopsy provided one or more diagnostic indications.
Regarding 52 patients with histological diagnosis of genetic
neuropathy in the period from 1991 (year of identification of
17p11.2 chromosome duplication as responsible for CMT1A)
(25, 26) to 2017, we assessed how many times diagnosis was
molecularly confirmed.We therefore considered 32 patients with
histological diagnosis of hereditary neuropathy, excluding 20
patients not molecularly analyzed. In 53.1% (n = 17) of cases
molecular confirmation of diagnosis was obtained, in 15.6%
(n = 5) molecular diagnosis was not achieved with a single
genetic test, and in the remaining 31.3% (n = 10) of patients
molecular diagnosis was not achieved after several tests.
In our series, neuropathies with histological picture suggestive
or diagnostic of vasculitis are 111, 95% (n= 105) of which axonal
and 5% (n = 6) with mixed features of demyelination and
axonal damage. Active Wallerian degeneration was highlighted
in 71% of cases (n = 79), demyelination and remyelination
were however present in 24% (n = 27) of patients, but
always secondary to primitive axonal damage. Inflammatory
infiltrates were found in 85% (n = 81) of cases, with chronic
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FIGURE 3 | (A) Average age of patients undergoing sural nerve biopsy during each year from 1981 to 2017. The increase in mean age is statistically significant with
r2 = 0.64 and p < 0.0001. (B) Percentage of minors compared to all the patients undergoing sural nerve biopsy year by year. The decrease in the percentage of
biopsies performed on minors is statistically significant, with r2 = 0.35 and p = 0.0001. ***p < 0.001.
FIGURE 4 | (A) Percentage of definite diagnoses year by year, from 1981 to 2017. There is a statistically significant increase in univocal diagnoses, with r2 = 0.12 and
p = 0.04. (B) Percentage of undetermined reports over the years. The decrease in the percentage of undetermined reports is statistically significant, with r2 = 0.3010
and p = 0.0004. *p < 0.05 and ***p < 0.001.
vascular changes predominating in the remaining cases (fibrous
obliteration of lumen, calcifications, recanalization and internal
elastic lamina fragmentation). In several cases, periavventitial
hemosiderin-containing macrophages were found, suggesting
previous hemorrhages. Axonal regeneration clusters, suggestive
of the end of the acute phase of damage, were highlighted in
46% (n = 51) of cases (Figure 6). In 6 cases, basal membrane
residues of Schwann cells were arranged to form Bungner
bands, expressing initial regeneration. When performed,
immunohistochemical analysis (IHC) with stains specific
for the antigenic determinants of various inflammatory cells
demonstrated infiltrates mainly composed of macrophages
(CD68+) and T-lymphocytes (CD45-RO+, CD4+/CD8+).
B-lymphocytes (CD20+) were less frequently reported. IHC
has replaced direct immunofluorescence (no longer performed
since 2010), which was instead used in the past to highlight
immunoglobulin, complement and fibrinogen deposits at
epineurial vessels wall.
For vasculitis, the ratio between affected females and males
was 1.8 (65% females and 35% males). Mean age at biopsy
(calculated on 77 patients whose age was known) was 62 years.
Considering 76 patients with known clinical suspicion, in 68%
(n = 52) vasculitis was already suspected, while in 32% (n = 24)
nerve biopsy modified the clinical diagnosis.
Since Genoa University is a reference center, many patients
come from other centers, so obtaining detailed clinical
information is difficult. Among 27 cases of vasculitic neuropathy
with clinical records completely available, vasculitis was: HCV-
related in 30% (n = 8), cryoglobulinemic in 4% (n = 1),
associated with Churg-Strauss syndrome in 11% (n= 3), ANCA-
associated with lung and peripheral nervous system (PNS)
involvement in 4% (n= 1), associated with connectivity’s in 11%
(n = 3), involving skin and PNS in 7% (n = 2), and involving
kidney and PNS in 4% (n = 1) of cases. Finally, vasculitis was
limited to PNS in the remaining 30% (n= 8) of patients.
In our series, amyloidotic neuropathies are 25 (in one
extra case the bioptic material consisted only of vascular
structures with amyloid deposits, but the nerve was not
assessable), 80% (n = 20) of which axonal, with active Wallerian
degeneration in 56% (n = 14) and regeneration clusters in
36% (n = 9) of cases. The remaining 20% (n = 5) of biopsies
showed coexistence of Wallerian degeneration and segmental
or paranodal demyelination. Vascular changes were noted in
40% (n = 10) of cases. Constantly found feature was the
deposit of amyloid substance in the epineurium, perineurium,
and endoneurium. Amyloid fibrils, stained with Congo red,
show a typical apple-green birefringence under a polarized light
microscope, which allows a certain etiological diagnosis.
DISCUSSION
Nerve biopsy is often the final step in the diagnostic work-
up of neuropathies of unknown origin. Although not generally
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FIGURE 5 | (A) Percentage of genetic neuropathies compared to the total of univocal diagnostic indications over the years. The decrease is statistically significant,
with r2 = 0.26 and p = 0.016. (B) Percentage of chronic inflammatory neuropathies compared to the total of unique diagnostic indications over the years. The
percentage increase is statistically significant, with r2 = 0.38 and p < 0.0001. (C) Percentage of vasculitic neuropathies compared to the total of unique diagnostic
indications year by year. The percentage increase is statistically significant, with r2 = 0.60 and p < 0.0001. (D) Percentage of toxic-deficient and metabolic
neuropathies compared to the total of univocal diagnostic indications year by year. The percentage decrease is statistically significant, with r2 = 0.22 and p = 0.004.
*p < 0.05, **p < 0.01, and ***p < 0.001.
FIGURE 6 | Simplified histological diagnostic pathway in the evaluation of suspected vasculitic neuropathy. The percentages derive from the analysis of 111 biopsies
suggestive of vasculitis reported at the Neurological Clinic in the period 1981–2017.
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necessary, biopsy has an essential role in particular situations,
identifying specific alterations.
Epidemiology and Variations Over the
Years
Observing the number of annually performed biopsies we
found a significant lower number of cases in which biopsy
has been prescribed, whereas in the’80 years we had a peak
of 60 biopsies, differently in the last years we had a constant
number of 20 biopsies per year. This reduction is likely
due to the development of alternative diagnostic methods,
such as genetic tests and additional laboratory investigations.
For example, in dysimmune neuropathies, immunological
tests detecting circulating antibodies against myelin (myelin-
associated glycoprotein, MAG), axonal (ganglioside), or Ranvier
node (155 neurofascin or contactin) components radically
changed the diagnostic approach. Furthermore, the percentage
of hereditary neuropathies diagnosed by sural nerve biopsy has
dropped down, since molecular tests, including next generation
sequencing, approaches are now available in most countries (27).
Consistently, the mean age of patients undergoing a nerve biopsy
significantly decreased. Nowadays, in children and adolescents
a sural nerve biopsy is required only in exceptional cases,
for instance to orient the genetic/molecular tests and to help
establishing the genotype-phenotype correlation (28). Since the
mean age of onset of vasculitic neuropathy is 60 years (29),
the age increase is also explained by the raised percentage
of vasculitic neuropathies in agreement with literature (30).
Metabolic and toxic-deficient neuropathies are less represented
in recent years and we can speculate that this happened because
of the improvement of social and health conditions.
In the first years of the study, in fact, inhalation of glue solvents
(N-hexane and methyl-butyl-ketone) and exposure to other
industrial toxic substances and heavy metals were certainly more
frequent. In 1973 a law was issued (Article 4) for the regulation
of the use of chemical reagents in industries and probably after
that also the consequences to the exposure have been decreased.
However, it must be considered that nerve biopsy is rarely
performed in the suspicion of toxic or deficient neuropathies
as diagnosis is usually achieved through careful medical history,
general and neurological examination, electrophysiology, and
laboratory investigations.
Moreover, out data confirm the higher frequency of vasculitic
neuropathies in females. This is predictable, since vasculitis
is generally immune-mediated and autoimmune diseases have
a higher incidence in the female sex (31). In other types of
diagnosis, however, the ratio between males and females led to
unexpected results. In particular, both vasculitic and amyloidotic
neuropathies were diagnosed 12 times more in males than in
females. Such a marked gender difference is not described in the
literature and probably is an artifact of our pool of data.
Vasculitis
Among vasculitic neuropathies, inflammatory infiltrates were
found in most cases (85%), but not in all samples, with
prevalent chronic vascular changes in the remaining 15%. After
the acute phase, inflammatory infiltrates may disappear leaving
the pathological hallmarks of fibrous obliteration of lumen,
calcifications, recanalization and fragmentation of internal elastic
lamina. In several cases, hemosiderin-containing macrophages
were found at the periavventitial level, indicating previous
bleeding. At the end of the acute phase, axonal regeneration
clusters often appear, but they may miss if the loss of fibers
was massive. Immunohistochemistry with specific antibodies
for the antigenic determinants of inflammatory cells has
been frequently used and is still essential for the precise
diagnosis of some dysimmune neuropathies. In contrast, direct
immunofluorescence, previously used to highlight epineurial
deposits of immunoglobulin, complement, and fibrinogen, has
not been used in our laboratory since 2010, following the
introduction of anti-MAG and anti-gangliosides antibodies
plasma dosage.
Non-systemic vasculitic neuropathies represent the 30% of
analyzed vasculitic cases. If nerve biopsy is useful, but not
always essential in patients with known systemic vasculitis,
histological examination is mandatory when PNS-limited
vasculitis is suspected.
Amyloidotic Neuropathy
Regarding amyloidotic neuropathies, Congo red staining and
apple-green birefringence under polarized light microscope
allow a certainty diagnosis. It is interesting to note that 20%
of biopsies presented mixed features of axonal and myelin
damage. The presence of segmental demyelination in amyloidotic
neuropathies, better evaluated by teasing, has been previously
described by some authors (32–34).
Diagnostic Yield of Sural Nerve Biopsy
The diagnostic yield of nerve biopsy is still a topic of discussion.
Over the 37 years examined, out of a total of 1,179 sural nerve
biopsies, the univocal diagnoses were 52.7%, the cases in which
the histology provided multiple diagnostic options 13.7% and
indeterminate reports 33.6%. Nerve biopsy was therefore helpful
in more than half of patients undergoing this test.
Considering only patients with a specific clinical etiological
hypothesis, histological examination confirmed the pre-biopsy
suspect in 57.2%, while in the remaining 42.8% of cases nerve
biopsy changed clinical diagnosis.
The diagnostic yield showed a progressive improvement, with
an increase in the number of univocal diagnoses. This may be
explained by the refinement of cases in which a pathological
exam is required and by the improving expertise of our center.
In our opinion, this supports the view that biopsies should
be processed and examined by expert personnel, in order to
both reduce artifacts and recognize the pathological hallmarks of
different diseases.
Considering indeterminate reports, in 71.5% of cases a precise
etiological hypothesis was missing even before biopsy. Even in
a retrospective study by Deprez et al., the lowest diagnostic
yield was when biopsy was performed in the absence of clinical
suspicion (14). Deprez also reported that only 20% of nerve
biopsies provided useful information in the absence of a clinical
suspicion, highlighting the need for appropriate clinical work-
up (20). As a consequence, the importance of carefully selecting
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patients undergoing nerve biopsy emerges. These results suggest
that, when a precise diagnosis not achieved after complete
clinical, laboratory and instrumental examinations, nerve biopsy
is rarely recommended.
If we considered our cohort of vasculitic neuropathies,
in 68% of patients a vasculitis was already suspected before
histological examination, while in 32% of cases, the diagnosis was
clarified only after the pathological exam nerve biopsy modified
clinical diagnosis.
These results about the diagnostic yield confirm what was
already known from previous literature (8, 11–14, 35–37).
Our work confirms a rather high diagnostic yield of nerve
biopsy, comparable to that obtained by Neundörfer et al. (8) and
Gabriel (13). since biopsy was helpful in guiding the diagnosis in
more than half of patients.
The diagnostic yield of this exam increases if patients are
carefully selected. Comprehensive clinical information are also
crucial since in most neuropathies a diagnosis can be obtained
by combining the results of biopsy with clinical features. The
importance of the choice of a clinically or electrophysiologically
affected nerve to be biopsied should be reiterated, since 12%
of examined nerves proved to be free of pathological changes.
However, in many cases of normal sural nerve, biopsy was
actually performed to exclude a peripheral neuropathic process in
the context of differential diagnosis from central nervous system
or motor neuron diseases.
According to literature, sural nerve biopsy provides the most
useful results in interstitial neuropathies, such as vasculitis,
granulomatosis, amyloidosis, or atypical forms of CIDP (7, 22).
In fact, the greatest diagnostic yield is obtained in asymmetric
or multifocal neuropathies, which are the typical features of
vasculitis (20).
CONCLUSIONS
This is the largest Italian study evaluating the diagnostic yield of
sural nerve biopsy, both for the number of biopsies and for the
period considered. Over time there was a progressive refinement
of biopsy prescription. Nevertheless, it remains a pivotal exam
in interstitial neuropathies, such as amyloidosis and vasculitis,
in particular in non-systemic vasculitic neuropathies, allowing a
diagnosis and addressing an appropriate treatment.
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